A virus carried by an estimated 95% of the global population may finally have met its match. Researchers in the United States have created a human-like antibody that completely prevented infection by the Epstein-Barr virus in laboratory models, marking a potential turning point against a pathogen linked to multiple cancers and chronic illnesses.
### A Decades-Old Viral Invader
### The Antibody Breakthrough
### From Lab Models to Human Impact
The Epstein-Barr virus has long been a formidable target. Unlike many viruses, EBV possesses a unique ability to bind to nearly every B cell in the human immune system, making it exceptionally difficult to block. Scientists at the Fred Hutchinson Cancer Center tackled this challenge by using mice genetically engineered to produce human antibodies. Their goal was to create monoclonal antibodies capable of stopping the virus from attaching to and entering human immune cells.
Their research, detailed in the journal Cell Reports Medicine, focused on two key viral proteins: gp350, which helps the virus latch onto cells, and gp42, which enables it to fuse with and invade them. From their specialized mouse model, the team identified ten promising antibodies—two targeting gp350 and eight targeting gp42. In subsequent tests on mice with human-like immune systems, one of the gp42-targeting antibodies provided complete protection against EBV infection upon exposure. An antibody targeting gp350 offered partial protection.
This work holds particular significance for a vulnerable group: transplant patients. More than 128,000 people in the U.S. receive solid organ transplants annually, and for them, a new EBV infection can be severe or even fatal due to immunosuppressive drugs. The research also validated a new platform for discovering protective antibodies against other stubborn pathogens. The findings represent a critical step, not a final cure, but they illuminate specific weak points on the virus that could guide the future development of both preventive therapies and vaccines for a near-universal infection.
